TheraVet logo
ALVET logo

TheraVetENXTPA:ALVET Stock Report

Market Cap €292.7k
Share Price
n/a
1Y-92.7%
7D0%
Portfolio Value
View

ALVET Stock Overview

A veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. More details

ALVET fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

TheraVet SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for TheraVet
Historical stock prices
Current Share Price€0.082
52 Week High€1.14
52 Week Low€0.063
Beta-0.51
1 Month Change-10.87%
3 Month Change-10.68%
1 Year Change-92.68%
3 Year Change-98.32%
5 Year Changen/a
Change since IPO-98.99%

Recent News & Updates

Recent updates

Shareholder Returns

ALVETFR BiotechsFR Market
7D0%3.9%-0.5%
1Y-92.7%-18.2%1.1%

Return vs Industry: ALVET underperformed the French Biotechs industry which returned -18.2% over the past year.

Return vs Market: ALVET underperformed the French Market which returned 1.1% over the past year.

Price Volatility

Is ALVET's price volatile compared to industry and market?
ALVET volatility
ALVET Average Weekly Movement22.0%
Biotechs Industry Average Movement7.6%
Market Average Movement4.5%
10% most volatile stocks in FR Market10.1%
10% least volatile stocks in FR Market2.3%

Stable Share Price: ALVET's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: ALVET's weekly volatility has increased from 14% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20176Gaetan Terrassewww.thera.vet/en

TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET, an injectable self-hardening phosphocalcic bone void filler for osteointegration, osteoinduction, and bone remodeling properties; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid, species specific plasma, and an active pharmaceutical component.

TheraVet SA Fundamentals Summary

How do TheraVet's earnings and revenue compare to its market cap?
ALVET fundamental statistics
Market cap€292.67k
Earnings (TTM)-€1.51m
Revenue (TTM)€918.32k

0.3x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALVET income statement (TTM)
Revenue€918.32k
Cost of Revenue€1.57m
Gross Profit-€647.82k
Other Expenses€866.37k
Earnings-€1.51m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin-70.54%
Net Profit Margin-164.89%
Debt/Equity Ratio27.5%

How did ALVET perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/24 23:43
End of Day Share Price 2025/02/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TheraVet SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura RobaDegroof Petercam Sponsored Research